Loss of HES1 expression is associated with extracellular matrix remodeling and tumor immune suppression in KRAS mutant colon adenocarcinomas
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Loss of HES1 expression is associated with extracellular matrix remodeling and tumor immune suppression in KRAS mutant colon adenocarcinomas ; volume:13 ; number:1 ; day:25 ; month:9 ; year:2023 ; pages:1-13 ; date:12.2023
Scientific reports ; 13, Heft 1 (25.9.2023), 1-13, 12.2023
- Creator
-
Wang, Lei
Gu, Wenchao
Zou, Bingqing
Kalady, Matthew
Xin, Wei
Zhou, Lan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-42234-7
- URN
-
urn:nbn:de:101:1-2024020710384293064043
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Lei
- Gu, Wenchao
- Zou, Bingqing
- Kalady, Matthew
- Xin, Wei
- Zhou, Lan
- SpringerLink (Online service)
Other Objects (12)
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression